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In Brief
Willemsen et al. screened the antiviral RIG-I pathway for regulators and identified and validated 22 kinases. They describe an inhibitory feedback loop mediated by DAPK1. Antiviral signaling activates DAPK1 kinase activity, which, in turn, inactivates RIG-I by direct phosphorylation.
INTRODUCTION
Detection of invading pathogens by the cells of an organism is key for countering infectious diseases. In vertebrates, virus infection elicits a rapid cell-autonomous immune response initiated by sensing of virus-derived pathogen associated molecular patterns (PAMPs) by germline encoded pattern recognition receptors (PRRs). The PRRs of the RIG-I-like receptor (RLR) family detect virus derived RNAs. RIG-I (official symbol: DDX58) senses double-stranded RNA (dsRNA) bearing a 5 0 -triphosphate group (5 0 ppp-dsRNA), a remnant of the RNA replication process of many RNA viruses. Upon binding to stimulatory RNA, RIG-I undergoes conformational changes allowing it to bind and activate mitochondrial antiviral-signaling protein (MAVS) (Abbas et al., 2013; Binder et al., 2011; Hornung et al., 2006; Patel et al., 2013) . Activated RIG-I/MAVS complexes recruit the kinases TBK1 and IKKε, which, in turn, recruit and activate the transcription factor IRF3 (Liu et al., 2015; McNab et al., 2015) , as well as the canonical IKKs (a, b, and g) to activate nuclear factor kB (NF-kB). Simultaneous activation of IRF3 and NF-kB results in the production of type I and type III interferon (IFN), proinflammatory cytokines as well as direct induction of antiviral genes such as IFIT1 (Chan and Gack, 2015) . Exposure of cells to IFNs induces expression of a broad panel of IFN stimulated genes (ISGs), which act in concert to protect from virus infections. While this acute response is vital to fight off ubiquitous viruses, overshooting and/or prolonged production of IFNs leads to detrimental side effects, participating in the immunopathology of various infections (Trinchieri, 2010) or even promoting the persistence of virus infection (Teijaro et al., 2013; Wilson et al., 2013) . On an organismal level, continuous IFN production is associated with autoimmune disorders (Buers et al., 2016; Crow and Manel, 2015) . Therefore, besides swift activation of the IFN system, timely and efficient shut down of the response is equally important (Ivashkiv and Donlin, 2014; Teijaro et al., 2013; Wilson et al., 2013) . In contrast to activation of RIG-I signaling, little is known about counter-regulatory mechanisms leading to the termination of signaling.
Constitutive dampening of RIG-I signaling and IFN production has been described recently. For example, activity-promoting ubiquitylation of RIG-I (Gack et al., 2007) is balanced by deubiquitylation (Cui et al., 2014; Fan et al., 2014) , and activating dephosphorylation of RIG-I by PP1 (Wies et al., 2013 ) is countered by inhibitory phosphorylation through PKC (Maharaj et al., 2012) . However, despite clear evidence of negative feedback on RIG-I, very little is known about the identity and regulation of these pathways. Importantly, to allow robust activation of type I IFN production shortly after virus infection, feedback mechanisms aiming at signal termination have to be activated with delayed kinetics. A few recent reports propose negative feedback involving proteasomal targeting of RIG-I (Arimoto et al., 2008; Kim et al., 2008; Chen et al., 2013) . However, given that RIG-I abundance is dramatically upregulated by IFN signaling, degradative mechanisms can only partially explain termination of signaling. Therefore, we hypothesized on the existence of negative-feedback mechanisms that directly affect RIG-I or immediate downstream signaling activity.
Here we used an unbiased kinome-wide RNAi screen to identify positive and negative regulators of RIG-I activation. We validated and characterized 22 genes, most of which have not been reported before to regulate RIG-I signaling. Among these, we identified a previously unknown negative-feedback mechanism that targets RIG-I activity and is mediated by death associated protein kinase 1 (DAPK1).
RESULTS
In order to identify kinases that regulate RIG-I signaling, a kinome-wide small interfering RNA (siRNA) screen was performed in an Huh7.5 RIG-I -based cell line (Binder et al., 2007) . Cells were stimulated by transfection of poly(I:C), which specifically triggers RIG-I-dependent signaling in these cells, and activation of antiviral signaling was quantified by assessing nuclear translocation of eGFP-tagged IRF3 ( Figure 1A ; STAR Methods). Analysis of primary screening data yielded 104 hit candidates that significantly (p < 0.05) altered IRF3 activation ( Figure 1B ; Data S1). figure. For results of other validation screens, see Figure S2 .
Primary Screening and Bioinformatics
Functional annotation analysis showed strongest enrichment of hit candidates in processes such as cytokinesis, phosphatidylinositol metabolism/signaling, and intracellular protein trafficking but also in disease-associated pathways, TLR signaling, and the innate immune response (Data S2). We further performed network analyses to assess the connectivity of our hit candidates based on a curated human protein-protein-interaction (PPI) network. We found several pairwise interactions between hit candidates, as well as a compact network of 15 interacting hit candidates ( Figure S1A ). In this network, AKT1 acted as a central hub directly linking to six other candidates, confirming its described role in regulating the induction of the IFN system (Gantner et al., 2012) . We further analyzed whether other candidates also directly link to the innate immune IFN network (Navratil et al., 2010) . Strikingly, while only four hit candidates were themselves part of the described IFN network (Navratil et al., 2010) , we realized that a substantial fraction of candidates (28 out of 104) directly interacted with a highly significant number of proteins (n = 27, p = 3 3 10 À13 ) of the IFN system (Figures 1C and S1C; Data S3) . This corroborated the quality of the primary screen, identifying genes that have previously not been recognized to be involved in antiviral innate immunity, but that are reasonable due to their close proximity to known members of the IFN response. Lastly, we analyzed our primary candidates for their overlap with published screens for host factors of different viruses. We found a highly significant number of hit candidates (30 out of 104, p = 7 3 10 À4 ) that had been identified as host factors for influenza A virus (FLUAV) (de Chassey et al., 2012) , which is known to be very sensitive to IFN and in particular to the RIG-I pathway (Killip et al., 2015) ( Figure 1C ; Data S3). This further fostered the notion, that our primary RNAi screen successfully identified genes involved in cellular processes directly or indirectly linked to the innate antiviral response system.
Validation Screening and Hit Characterization
Primary screening identified 104 genes modulating RIG-I/IRF3 signaling. In order to stringently validate hits, the 58 most prominent candidates (based on p value and literature, Data S1) were subjected to three independent rounds of validation screening, employing siRNAs, cell lines, and reporter systems different from the primary screen (see Figures 1A, 2A , and S2). The most robust validation screen (highest Z scores) was based on A549 cells infected with a Renilla luciferase encoding Rift Valley fever virus (RVFVDNSs_RLuc), which is known to very efficiently trigger RIG-I signaling (Kuri et al., 2010) . The readout in this setting was the degree of RIG-I/IRF3/IFN-mediated inhibition of RVFV replication ( Figure 1D ). We considered a hit validated when its effect was significant in the primary, the RVFV and at least one other validation screen (see STAR Methods). Twentytwo genes satisfied these criteria and are therefore considered high-confidence hits reproducibly affecting RIG-I signaling (Figures 2 and S2C; Data S1). Twenty-one identified hits (AAK1 was excluded for technical reasons) were further characterized with respect to their effect on RIG-I-mediated IRF3 activation upon knockdown or overexpression in 293T
RIG-I cells. For the knockdown setting, the respective siRNA yielding the strongest effect in validation screening was used and IRF3 activity (IFIT1 promoter) luciferase reporter activation as well as endogenous IFIT1 mRNA production were assessed ( Figure 2A , upper panel). To complement gene silencing, we further obtained cDNAs for all hit genes and assessed the effect of their overexpression on RIG-I-mediated IRF3 activation. Expression of 16 out of the 21 tested genes lead to dose-dependent modulation of IRF3 activation upon RIG-I stimulation ( Figure 2A , lower panel). For several of these genes, the direction of the effect of overexpression was in agreement with the knockdown phenotype (i.e., inverse direction) and also confirmed the phenotype observed in the screens (Figure 2C ). Another group of hit genes were ''notorious switchers,'' i.e., reproducibly showing significant effects in all tested settings but with irreproducible directions. These genes will be challenging but very exciting to follow up on in future studies, as their abundance and/or activity seems to require very fine balancing, which might suggest central roles in the regulatory circuits they are involved in. In order to establish the relevance of the identified hits within the authentic life cycle of a relevant human pathogen, hit genes were silenced in human lung epithelial A549 cells prior to infection with FLUAV. Staining the viral NP protein and subsequent flow-cytometric analysis demonstrated reproducible and potent effects on the number of FLUAV positive cells for a majority of genes ( Figure 2B ).
In summary, our high-throughput screen identified 22 genes that reproducibly and significantly affected signaling through the RIG-I pathway, and most of which have not been implicated with innate antiviral signaling before.
Death-Associated Protein Kinase 1 Inhibits RIG-IMediated Signaling Death-Associated Protein Kinase 1 (DAPK1) was one of three genes that stood out by showing significant effects of consistent direction throughout all tested assays ( Figure 2C ). DAPK1 is a 160-kDa Ca 2+ -/calmodulin (CaM)-dependent serine/threonine kinase, comprised of an N-terminal kinase domain followed by a regulatory CaM binding domain, eight Ankyrin repeats, a cytoskeleton associating ROC-COR domain and a C-terminal death domain (schematic in Figure 4A , interaction network in Figure S1B) (Carlessi et al., 2011) . It has been described to be involved in the regulation of a variety of cellular processes such as apoptosis, autophagy, cell motility, and inflammation (Bialik and Kimchi, 2014) .
From our screening, DAPK1 was identified as a negative regulator of RIG-I/IRF3 signaling, with its silencing leading to increased transcriptional activity of IRF3, and overexpression leading to a profound decrease (Figure 2A) . Accordingly, silencing of DAPK1 had profound negative effects on viral replication, both for RVFV ( Figure 1D ), as well as for FLUAV ( Figure 2B ). We further validated this effect on FLUAV by immunofluorescence analysis of infected cells ( Figure 3A ) and detailed flow cytometry (FACS) analysis ( Figure 3B ), as well as in virus production assays ( Figure 3C ), clearly demonstrating a substantial decrease of viral replication in DAPK1-silenced cells.
We then further dissected the inhibitory effect of DAPK1 onto the outcome of RIG-I signaling. In order to discriminate whether DAPK1 specifically affects activation of either IRF3 or NF-kB, or whether it regulates the pathway as a whole, we separately analyzed its effects on the activation of IRF3, NF-kB, and on the expression of IFN-b. Upon silencing, RIG-I-induced NF-kB activity was increased similarly to IRF3, and accordingly expression of IFN-b mRNA was enhanced ( Figure 3D ). This effect was reproducible in different human cell lines and in primary mouse lung fibroblasts ( Figures S3A-S3C ), as well as with different siRNAs (Figures S3C and S3D) . Reciprocally, transient overexpression of DAPK1 lead to a dose-dependent inhibition of both IRF3 and NF-kB activation upon RIG-I stimulation, as well as decreased levels of IFN-b mRNA ( Figure 3E ). These observations suggest a role of DAPK1 in regulating RIG-I signaling at the level or upstream of MAVS.
DAPK1 Kinase Activity and Ankyrin Repeats Are Essential for RIG-I Pathway Inhibition
In order to dissect which domains of DAPK1 ( Figure 4A ) are essential for mediating its inhibitory effect on RIG-I signaling, a series of deletion mutants were tested for their ability to inhibit IRF3 activation. The death domain, the ROC-, and the regulatory CaM-binding domains were dispensable for the inhibitory effect on IRF3 activation. In contrast, a construct lacking both, the Ankyrin repeats and the DAPK1  DDR1  BMX  DGKD  EPHA2  CDKL3  FASTK  GK2  IRAK1  IRAK2  IRAK4  ITPKC  MARK2  MATK  RIOK3  RIPK4  RPS6KA2  SH3BP4  SKP2 RIG-I unstim. ROC/COR domains, lost its inhibitory potential ( Figure 4B ), suggesting the Ankyrin repeats domain to be essential for the observed phenotype. Indeed, we could identify a minimal construct comprising only the kinase-, CaM-binding, and Ankyrin repeats domains (KinjCaMjAnk) to be sufficient to confer the complete inhibition of IRF3 activation ( Figure 4C ). Neither the Ankyrin repeats nor the kinase domain by themselves were sufficient to inhibit IRF3 activation ( Figure 4C ). Based on these findings, we hypothesized that the Ankyrin repeats were required for interaction with a potential target, which would then be phosphorylated by the kinase domain. To test whether kinase activity is indeed essential for the down-modulation of RIG-I signaling, we generated enzymatically inactive KinjCaMjAnk variants. DAPK1 kinase activity has been described to be strictly inhibited by autophosphorylation at serine 308 (S308); only upon removal of this phosphate DAPK1 kinase becomes active again (Shohat et al., 2002). We therefore generated phosphomimetic (S308D) and phosphoablatant (S308A) mutants as described before (Shohat et al., 2001 ) and tested them for their inhibitory potential on IRF3 activation. Indeed, the constitutively active non-phosphorylatable (S308A) KinjCaMjAnk variant inhibited RIG-I signaling at least as strongly as wildtype DAPK1, whereas the kinase inactive phosphomimetic (S308D) variant rescued IRF3 activity to a large extent (Figure 4D) . Comparable results were obtained with a variant that harbored a 73-aa deletion of the active site, and, to a lesser extent, a variant with a mutated ATP acceptor lysine at position 42 (K42A) ( Figure 4D ). The lower rescue efficiency of the latter (K42A) likely stems from substantial residual kinase activity of this mutant when expressed in cells (Figure S4B) in contrast to the published in vitro setups (Cohen et al., 1997) . These findings support the notion that DAPK1's capacity to inhibit antiviral signaling strongly depends on its Ankyrin repeats domain as well as on the enzymatic activity of its kinase domain. 
Stimulation of DAPK1 Kinase Activity upon RIG-IMediated Antiviral Signaling
Under physiological conditions, the enzymatic activity of DAPK1 is autoinhibited by default. The most critical step to activate its kinase activity is dephosphorylation of p-S308, which can be triggered by mitochondrial uncoupling, e.g., by treatment of cells with a protonophore such as CCCP (Shang et al., 2005) . We tested whether antiviral signaling could activate DAPK1 as well. We therefore assessed activation of endogenous DAPK1 by probing for the phosphorylation status of S308 upon infection of A549 cells with Sendai virus or stimulation by transfection of the RIG-I-specific ligand 5 0 ppp-dsRNA. Stimulation of RIG-I by virus infection ( Figure S5 ) or 5 0 ppp-dsRNA substantially decreased the level of S308 phosphorylation over time, comparable to the positive control CCCP (Figures 5A and 5B ). Dephos- phorylation was accompanied by a moderate decrease in total DAPK1 levels, which is in agreement with the reported rapid degradation of activated DAPK1 (Jin et al., 2006) . Interestingly, in our kinetic experiments phosphorylation of TBK1 and IRF3, established markers of active RIG-I signaling, increased up to 8-to 12-hr post-stimulation and then started to decrease despite continuously increasing levels of RIG-I (being an ISG). Intriguingly, this pathway deactivation kinetically coincided with the strong activation of DAPK1 after 8 hr ( Figure 5B ). To confirm that the observed activation of DAPK1 was mediated by antiviral signaling, we performed the same experiment in RIG-I-deficient (CRISPR-KO) A549 cells. In fact, DAPK1 activation was only observed in A549 WT , but not in RIG-I-deficient cells ( Figure 5C ). Further, activation of DAPK1 was independent of IFN signaling, as exogenous addition of IFN-a did not trigger dephosphorylation of DAPK1 ( Figure S5B ). This indicated that direct, intracellular signaling events lead to the activation of DAPK1.
Taken together, we concluded that kinase-active DAPK1 is a potent inhibitor of RIG-I/IRF3 signaling, and that DAPK1 itself is activated upon stimulation of RIG-I signaling. This strongly suggested that DAPK1 acts as a negative-feedback regulator of this antiviral signaling pathway. To corroborate this hypothesis, we performed loss-of-function experiments. Upon silencing of DAPK1 by siRNA, stimulation of cells by 5 0 ppp-dsRNA lead to an increased and prolonged expression of IFIT1 and IFN-b mRNA ( Figures 5F and 5G) . Importantly, intracellular protein levels of IFN-b closely resembled the kinetics of the mRNA levels ( Figure 5 , compare panels 5D and 5E to 5G), and also secreted levels of IFN-b protein were increased upon DAPK1 silencing ( Figure 5H ). A repetition (total n = 3) of this experiment is shown in Figures S5C-S5H , in which secretion rates (as opposed to accumulated levels in supernatant) were determined for IFN-b. This observation of increased production and secretion of IFN-b is very consistent with the observed strong inhibition of virus replication upon DAPK1 silencing (Figure 3) . Collectively, these data establish DAPK1 as a potent negative-feedback regulator of the RIG-I antiviral signaling pathway. 
DAPK1 Physically Interacts with and Phosphorylates RIG-I
The simplest interpretation of our findings would be that DAPK1, upon activation, interacts with and phosphorylates a member of the RIG-I-initiated signaling cascade. We therefore screened the most prominent canonical signal transducers of the pathway, namely, RIG-I, MAVS, TRADD, TBK1, IKKε, IRF3, and IRF7 for interaction with DAPK1. Co-precipitation experiments indicated that DAPK1 did not interact with MAVS, TRADD, TBK1, IKKε, and IRF3 and only a very weakly and non-reproducibly with IRF7 ( Figure S6 ). Strikingly, however, RIG-I robustly co-precipitated with DAPK1 ( Figures 6A, 6B , and S6). Based on our functional findings (Figure 4) , we hypothesized that RIG-I would also interact with the minimal KinjCaMjAnk construct, but not or only weakly with the kinase domain (KinjCaM). This prediction was confirmed in experiments using these truncated variants of DAPK1 ( Figure 6C ). Of note, one of the validation screens employed RIG-I 2CARD to stimulate signaling and this was the only assay, in which DAPK1 silencing did not have a significant effect (p = 0.12, Data S1). This also supported the notion of DAPK1 directly targeting RIG-I.
Next, we investigated whether RIG-I might constitute a direct substrate of the DAPK1 kinase. For this purpose, we performed in vitro kinase assays using Strep-tag affinity-purified DAPK1
KinjCaMjANK and recombinant RIG-I in the presence of g 32 P-ATP. As expected from literature (Shohat et al., 2001 ), DAPK1 strongly autophosphorylated itself, but, strikingly, it also robustly phosphorylated RIG-I ( Figure 6D ). This phosphorylation was approximately 50% less efficient in the absence of CaM and basically absent in the enzymatically inactive DAPK1 K42A control, highlighting the specificity for DAPK1 and ruling out artifacts by potentially co-purifying cellular kinases. In order to identify the residues in recombinant RIG-I that are phosphorylated by DAPK1, we analyzed in vitro phosphorylated RIG-I by mass spectrometry. Seven phosphorylation sites on RIG-I were unambiguously identified in samples containing enzymatically active DAPK1, but not the enzymatically inactive DAPK1 K42A variant or an unrelated control protein ( Figure 6E ).
The identified phosphoserines and phosphothreonines clustered in two distinct regions of the RIG-I protein. Cluster I was located in the Hel2 region of the helicase domain, and cluster II in the pincer domain of RIG-I ( Figure 6F ). In addition, we further identified the very N-terminal serine at position 8 (S8) to be phosphorylated by DAPK1. Notably, phosphorylation of this residue by PKC has been reported before to negatively regulate RIG-I activity (NistalVillá n et al., 2010; Wies et al., 2013) , which is in line with the observed inhibitory effect of DAPK1 onto RIG-I signaling.
Phosphorylation of RIG-I Threonine 667 Impairs 5 0 pppdsRNA Binding and Abolishes Antiviral Signaling The RIG-I phosphosites in cluster I and II were previously not known. To functionally characterize their effect, we generated phosphomimetic mutants by replacing serines and threonines by glutamic acid or, as a control, by non-phosphorylatable alanines ( Figure S7A ). RIG-I mutants were expressed in 293T cells that are virtually devoid of RIG-I, and cells were stimulated by transfection of 5 0 ppp-dsRNA. As expected, the phosphomimetic of S8 (S8E) significantly reduced IRF3 activation to about 30% of wild-type RIG-I. Mutation of the two residues of cluster II did not affect signaling, but mutation of cluster I completely abolished RIG-I induced IRF3 activation ( Figure 7A ). Cluster I resides in the helicase motif IVa of the Hel2 region, which was shown before to be essential for RIG-I signaling (Devarkar et al., 2016) . Upon binding of RIG-I to certain RNAs, such as 5 0 -OH-hairpinRNA, the motif forms an a-helix and a loop, with cluster I residue T667 residing at the very tip of this loop (Figure 7B) . It was intriguing to speculate that phosphorylation at this prominent position would interfere with RIG-I activation. In line with this hypothesis, phosphomimetic replacement of this single residue by glutamic acid (T667E) sufficed to render RIG-I completely unresponsive to transfected 5 0 ppp-dsRNA ( Figure 7A ). Furthermore, less 5 0 ppp-dsRNA could be coprecipitated with RIG-I T667E and RIG-I T667E/T671E as compared to RIG-I WT ( Figure 7C ). To confirm the strong inhibitory effect of T667 phosphorylation in a more physiological setting, we stably reconstituted A549 RIG-I KO cells with RIG-I by lentiviral transduction, either with the wild-type (WT) form or the phosphomimetic variants, and infected these cells with FLUAV. For WT and S8E, we observed robust induction of IFIT1 protein and secretion of IFNl upon FLUAV infection, whereas phosphomimetics of the cluster I residues, including the individual T667E mutation, almost completely abrogated IFIT1 and IFNl induction ( Figures 7D and 7E) . Accordingly, FLUAV replication was substantially more efficient in cells harboring RIG-I T667E than RIG-I WT as evidenced by FLUAV-NP-specific FACS analysis ( Figure 7F ). Together, these findings offer a sound explanation for the strong inhibitory effect of enzymatically active DAPK1 on RIG-I pathway activity. In light of the observed activation of DAPK1 upon antiviral signaling and the increased and prolonged production of IFN-b upon knockdown of DAPK1, these data strongly support a model wherein DAPK1, by phosphorylation of RIG-I, acts as a negative-feedback regulator of RIG-I/IRF3 signaling, involved in the timely downregulation of antiviral signaling and the re-establishment of cellular homeostasis.
DISCUSSION
We have performed an unbiased screen across all annotated human kinases for regulators of antiviral RIG-I signaling and identified 104 genes significantly modulating IRF3 activation upon stimulation of RIG-I by dsRNA. Two elegant studies have been published screening genome-wide for factors regulating RLR signaling, one from the Krishnan lab (Pulloor et al., 2014) and one from the Lamarre lab (Baril et al., 2013 ). The Krishnan screen revealed a functionally important role of inositol pyrophosphates in the induction of type I IFN. While our screen did not identify (or not cover) the same genes as theirs, functional annotation clustering did reveal a strong enrichment of candidate genes in phosphatidylinositol and inositolphosphate metabolism and signaling, including PI3K enzymes and ITPKC (Data S2, cluster 2). The screen by Lamarre identified Wnt/b-catenin signaling as an inhibitory system for RLR signaling and IFN-b induction. In line with their model, in our primary screen we found significant effects for isoforms of canonical downstream kinases of Wnt-signaling, such as GSK3a and GSK3b or the CSNK1A1 paralog CSNK1G2 and the closely related CSNK1A1L. Moreover, our screen identified AKT1, which can also directly activate b-catenin (Fang et al., 2007; Luo et al., 2015) , and several interacting proteins ( Figure S1A ). The observation that the two published studies and ours, despite different technical setups and siRNA libraries, identify similar pathways, underscores the quality and biological relevance of the three screens. It further highlights the general importance to compare high-throughput data on a functional or pathway level, rather than on the level of individual genes.
Our primary screen did not identify canonical antiviral signal transducers, such as IKKε or TBK1, which might be due to inherent redundancy of these kinases. Instead, it identified genes from different cellular pathways and functional modules that are directly or indirectly linked to the antiviral response, which was also highlighted by PPI network analyses and functional annotation clustering. One such functional module is glucose metabolism (Data S2, cluster 17): out of four kinase activities required for core glycolysis, isoforms of three were identified as hit candidates in our screen (HK2, PKLR, and PFKL). This is particularly interesting in the light of mounting evidence for a major functional crosstalk between metabolism and various aspects of immunity (Haneklaus and O'Neill, 2015; Wolf et al., 2016) .
In three independent rounds of secondary screening, 22 hits could be validated. Twenty-one of them were further studied in a variety of different assays, providing a rich source of functional data. Ongoing and future studies can build upon these data and are likely to reveal exciting insight into the regulation of innate immunity and its interplay with other cellular processes. DAPK1 was picked for further in depth characterization as it showed a very robust and interesting phenotype in our assays:
(1) ectopic expression of DAPK1 leads to profound and dosedependent inhibition of RIG-I-mediated IRF3 and NF-kB activity as well as IFN-b expression; (2) silencing of the gene promotes these activities; (3) silencing of DAPK1 boosts IFN-b production and substantially suppresses replication of two unrelated viruses, RVFV and FLUAV. Together, these findings establish DAPK1 as an inhibitor of RIG-I signaling. An involvement of DAPK1 in antiviral responses has only recently been described by one study, which, in the contrary to our present work, found DAPK1 to promote IRF3 and IRF7 activation and IFN-b production (Zhang et al., 2014) . The reason for the contradictory findings remains enigmatic; so far, we were not able to obtain the cells and reagents from the authors and, hence, cannot rule out cell-type-specific differences between their 293 cells and the four different human (Huh-7, 293T, A549) and murine (primary fibroblasts) cell types used in our study. Possibly, a second, independent effect of DAPK1 at the level of the IRFs is dominant in their cell system. This would also be compatible with their observation of the effect's being independent of DAPK1 kinase-activity, which, again, is in stark contrast to our findings.
We found that the active kinase domain in conjunction with the Ankyrin repeats of DAPK1 are required and sufficient to mediate inhibition of RIG-I signaling. This argues for a classical phosphorylation dependent regulation of the RIG-I pathway upon activation of DAPK1. It has been described, that DAPK1 gets activated upon mitochondrial depolarization (Shang et al., 2005) . Indeed, treatment of cells with the protonophore CCCP leads to activation of DAPK1 and to a decrease in RIG-I stimulated IRF3 activation (data not shown). This could, however, also be due to indirect effects, as mitochondrial integrity has been shown to be essential for MAVS signaling (Jacobs and Coyne, 2013; Koshiba et al., 2011) . Very interesting, though, is our observation that DAPK1 becomes activated upon RIG-I dependent triggering of antiviral signaling. Strikingly, the kinetics of DAPK1 activation shortly precedes the deactivation of RIG-I signaling. Knowing that dephosphorylated (= activated) DAPK1 potently inhibits RIG-I signaling, this finding strongly suggests that the kinase constitutes a negative-feedback regulator of antiviral signaling.
Screening for direct interactors of DAPK1 within the antiviral signaling cascade, we could, in contrast to the study by Zhang et al. (2014) , not find robust interaction with IRF3 or IRF7. Instead, we found that DAPK1 interacts with the PAMP sensor RIG-I. This interaction is rather weak and can only be reliably shown in overexpression conditions. Nevertheless, interactions of kinases with their substrates are notoriously weak and extremely transient; hence, the identified interaction is very likely meaningful. By biochemical in vitro phosphorylation assays, we demonstrated that RIG-I in fact is a substrate of DAPK1 and becomes phosphorylated at a number of serine and threonine residues. In line with our model of kinase activity-dependent inhibition of RIG-I, one of these residues was serine 8, phosphorylation of which by PKCa and b has been described before to negatively regulate RIG-I activation (Nistal-Villá n et al., 2010; Wies et al., 2013) . It is intriguing to speculate that S8 phosphorylation status and corresponding RIG-I signaling competence is regulated by the dynamic equilibrium between (possibly constitutive) phosphorylation by PKC, dephosphorylation by PP1 (Wies et al., 2013) and feedback-induced phosphorylation by DAPK1. Strikingly, however, we identified another, previously undescribed residue in RIG-I that is phosphorylated by DAPK1 and shows a substantially larger effect: a phosphomimetic of threonine at position 667 (T667E) virtually completely abrogates RIG-I signaling in response to 5 0 ppp-dsRNA, whereas the nonphosphorylatable mutation T667A is almost as effectively signaling as the wild-type. T667 resides in motif IVa of the helicase domain, a highly interesting motif that is intrinsically disordered in the unbound protein (Luo et al., 2011) , thereby representing an ideal kinase substrate (Iakoucheva et al., 2004) . It was shown previously that upon binding to 5 0 -OH-but not to 5 0 ppp-hairpinRNA, this motif forms into a loop-a-helix conformation (Devarkar et al., 2016) , in which T667 marks the tip of the loop structure protruding furthest toward the terminus of the bound RNA. Presence of a phosphoryl-threonine at position 667 might stabilize this structure by electrostatic interaction with a basic residue in the regulatory domain (K858, Figure 7B ). It therefore is intriguing to speculate that phosphorylation or phosphomimetic mutation of T667 might impact RNA binding, and our RNA-co-precipitation experiments also hint toward this possibility. However, more meaningful equilibrium based biochemical assays will be required to definitely answer this question.
Taken together, our kinome-wide RNAi screening approach identified 22 genes modulating antiviral signaling through the RIG-I/IRF3 axis. One of these genes, DAPK1, could be established as a potent negative-feedback regulator that is activated upon virus infection and antiviral signaling. Subsequently, it leads to downregulation of the signal generated by RIG-I by means of inhibitory phosphorylation of the sensor at residues including the previously described S8 and the here-identified T667. Phosphorylation of T667 almost completely abrogates RIG-I signaling in response to 5 0 ppp-dsRNA, which is the major ligand for this receptor during virus infection. Accordingly, knockdown of the feedback regulator DAPK1 leads to a profound inhibition of replication of the human pathogens RVFV and FLUAV, whereas mimicking constitutive phosphorylation of RIG-I by DAPK1 results in a drastic increase of FLUAV replication. The impact of this study will be manifold, ranging from a better insight into the physiological termination of antiviral inflammatory signaling, improving the structural understanding of ligand binding and activation of RIG-I, to improving the design of novel synthetic agonists and antagonists of RIG-I for clinical use.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Silencer Human Kinase siRNA Library Ambion AM80010V3 primers Sigma-Aldrich see Tables S3 and S4 siRNAs QIAGEN/MWG/Sigma-Aldrich see Table S2 Software Generation of primary cells Primary mouse lung fibroblasts were generated from female C57BL/6N mice (Charles River, Sulzfeld, Germany). Lung tissue was cut into aprx. 1 mm pieces and digested with Liberase TM (Sigma Aldrich, Germany) for 30 to 90 min at 37 C in DMEM. Liberase activity was stopped by washing 3 times with 10% FCS in DMEM. Digested lung pieces were cultured under above described culturing conditions for at least one week to allow fibroblasts to migrate out. Lung pieces and debris were then washed away and fibroblasts were trypsinized and passaged normally for a maximum of three passages. Generation of stable cell lines Stable cell lines were generated by lentiviral transduction. Briefly, lentiviral particles were produced on 293T cells by calcium phosphate transfection with the following three plasmids at a 3:1:3 ratio: (i) pCMV-DR8.91, coding for HIV gag-pol; (ii) pMD2.G, encoding the VSV-G glycoprotein; and (iii) a lentiviral vector based on the pWPI vector harboring the gene of interest or lenti-CRISPR-RIG-I. pCMV-DR8.91 and pMD.2G and pWPI were kind gifts from Prof. Didier Trono (Lausanne, Switzerland). Cell-free supernatants were harvested 48, 56 and 72 hr after transfection and used for transduction of target cells. Successfully transduced cells were selected by supplementing the culture medium with 5 mg/ml blasticidin, 1 mg/ml puromycin or 1 mg/ml geneticin (G418).
siRNA screening Primary screen Cell arrays were prepared by printing Ambion Silencer Human Kinase siRNA Library (AM80010V3) and Lipofectamine 2000 (Life Technologies) on LabTek chamber slides (Thermo Scientific, Germany) as described before (Erfle et al., 2007) . The library covered 719 genes with three siRNAs per gene. Huh7.5
RIG-I cells were stably transduced with an N-terminal fusion of IRF3 with eGFP to yield Huh7.5 RIG-I/eGFP-IRF3 . Cells were seeded on cell arrays at a density of 2x10 5 cells per chamber slide and were stimulated 48 hr post seeding by transfection of 500 ng poly(I:C), 3 mg poly(C) and 13 ml of Lipofectamine 2000 according to the manufacturer's protocol. Cells were fixed with 4% paraformaldehyde 2 hr after poly(I:C) transfection and nuclei were stained using Hoechst 33342. Cell arrays were imaged using the automated IX81 inverted screening microscope (Olympus). Screening was performed in 12 replicates. Acquired images underwent automated and manual quality control to exclude areas of aberrant staining. Then, the images were automatically analyzed using an adaption of the image analysis method by Matula and colleagues (Matula et al., 2009) , which comprises segmentation of cell nuclei and quantification of mean GFP signal intensities within the nuclei and in a 6 pixel region surrounding the nucleus (i.e., cytoplasmic signal).
Bioinformatics analyses
Functional annotation clustering was performed using the online analysis tool DAVID (Huang da et al., 2009a, b) version 6.8, with the 104 primary hit candidates as a query dataset and the 719 genes from the library defining the background. Protein-protein-interaction (PPI) network analyses of hit candidates were performed on a human interactome map. The full interactome was generated based on a download of iRefIndex 9.0 (Razick et al., 2008) , post-processed in several steps including filter applications in order to reconstruct a high-quality human interactome. As an example, only protein-protein interactions found at least twice (in two distinct publications or through two distinct experimental methods) were retained. This allowed to dramatically improve the trustworthiness of the full network. The IFN-related network is an update of the earlier published network (de Chassey et al., 2012) . Protein interaction networks were visualized with Cytoscape (Smoot et al., 2011) . Enrichment analysis of hits in lists of host factor genes for different viruses was based on lists assembled in previous work (de Chassey et al., 2012) . In all cases, Exact Fisher tests assessing the significance of hit-related proportions were performed using the kinome siRNA library as background.
Validation screens
From the primary hit candidates, 58 top ranking genes (based on p values < 0.05 or prior knowledge from literature) were chosen for secondary validation screening. Three different rounds of validation screening have been performed using cell lines, readouts and siRNAs distinct from the primary screen. Two siRNAs per gene were ordered from QIAGEN (Hilden, Germany); QIAGEN siRNA IDs can be found in Data S1. Transfection of siRNA was done using HiPerfect (QIAGEN) according to the manufacturer's protocol.
Validation screen 1 -VSV vRNA: In 9 biological replicates, 293T
RIG-I cells (at 7000 cells/well, 96-well format) were transfected with 10 nM siRNA. 48 hr later cells were transfected with IFIT1 promoter firefly luciferase and SV40-early promoter Renilla luciferase reporter plasmids by Effectene (QIAGEN). 8 hr later cells were stimulated with 40 ng/well Vesicular Stomatitis virus (VSV) vRNA (RNA prepared from VSV containing culture supernatants). 16 hr post stimulation, cells were lysed and luciferase activity was measured. Cloning and plasmids Expression constructs of hit genes Expression constructs for hit genes were either taken from the ORFeome library, were kind gifts of generous colleagues or were cloned from cells by RT-PCR. Final constructs contained an affinity tag (V5, HA, Myc or Flag) and were under transcriptional control of the CMV promoter. For details, see Table S1 . DAPK1 truncations and point mutants Truncations, domain deletions and point mutants of DAPK1 are based on the above mentioned CMV-driven expression construct (pcDNA) and were cloned using overlap PCR with the primers listed in Table S4 . For internal deletions or point mutations indicated overlap primers were used in combination with forward and reverse primers for full-length DAPK1 or KD + CaM + Ank Reverse primer in case of KD + CaM + Ank S308A/D and K42A. RIG-I point mutants RIG-I phosphomutants were generated by whole plasmid mutagenesis using the primers listed in Table S4 WT and RIG-I mutants were cloned by LR reaction using LR clonase II (life technology) into a gateway compatible pWPI. Expression from pWPI vectors is driven by an EF1-alpha promoter.
Lenti-CRISPR-RIG-I vector RIG-I specific gRNA (CTGTTGGAGCTCCAGGAGGA) was cloned into the lenti-CRISPR plasmid (Addgene #52961) via BsmBI to generate lenti-CRISPR-RIG-I.
Gene silencing by siRNA Cells were seeded in 24-well plates and subsequently transfected by RNAiMax (Invitrogen) with a final concentration of 10 nM siRNA. siRNAs for validation screening were purchased from QIAGEN; QIAGEN siRNA IDs are listed in Data S1. For all further characterization experiments beyond screening, those siRNAs yielding the strongest effect in validation screening, respectively, were chosen (listed in Table S2 ). Additional mouse and human DAPK1 siRNA were purchased from Sigma-Aldrich (listed in Table S2 ) 48 hr post transfection cells were transfected with IFIT1 promoter (IRF3) or NFkB luciferase reporter or left untreated for mRNA measurements. 8 hr later cells were stimulated for further 16 hr, before cells were lysed and subjected to mRNA quantification or measuring of luciferase activity (see ''RIG-I signaling assays'' below). Readout by luciferase reporter assay IRF3 or NFkB activation was measured using the promoter luciferase reporter constructs pGL3B/561 (kind gift of Ganes Sen, Cleveland) or pGL4.32[luc2P/NFkB-RE/Hygro] (Promega), respectively. Reporter plasmids were co-transfected with pRL-SV40 for normalization and the stimulatory RNA during stimulation of cells (see above), if not stated otherwise. For the luciferase assay (24-well format), stimulated cells were lysed in 100ml luciferase lysis buffer (1% Triton X-100, 25 mM glycyl-glycin [pH 7.8], 15 mM MgSO 4 , 4 mM EGTA, 10% glycerol [99%]) directly in the well. Plates were frozen and stored at À80 C until measurement. Firefly luciferase was measured applying 400 ml luciferase assay buffer (15 mM K 3 PO 4 [pH7.8], 25 mM glycyl-glycin [pH 7.8], 15 mM MgSO 4 , 4 mM EGTA) with freshly added 1 mM DTT, 2 mM ATP and 1 mM D-Luciferin. Renilla luciferase was measured after firefly, applying 400 ml luciferase assay buffer supplemented with 1.43 mM coelenterazine (PJK, Germany) and using a 480 nm filter (480m20BREThs, Berthold) to exclude the firefly signal. After measurement of Renilla, luciferase activity was quenched by addition of 100 ml of 10% SDS to prevent bleedthrough into the neighboring wells. Measurements were performed using a Mitras 2 multimode plate reader LB942 (Berthold, Germany). Firefly luciferase, reporting IRF3 and NFkB activation, was normalized to respective Renilla value to normalize for transfection efficiency and cell numbers.
Overexpression of hit genes

Readout by quantitative RT-PCR
To assess IRF3 activation in the absence of artificial promoter reporters, transcription of endogenous IFIT1 or IFN-b genes was measured by quantitative RT-PCR. Total RNA was isolated from stimulated cells using the NucleoSpin RNA Kit (Macherey-Nagel) according to manufacturer's protocol. For cDNA generation, 1 mg of total RNA was used and reverse transcribed with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to manufacturer's instructions by using a thermal cycler. Quantitative real-time PCR was performed with SYBR Green (Biorad) and gene-specific primers (see Table S3 ) using the CFX96 real-time system (Biorad). Primers were designed using PrimerBlast (Ye et al., 2012) and requiring exon-exon junction overlap. mRNA levels were normalized to GAPDH and relative levels were determined using the DDc t method.
Readout by immunoblot
In order to determine IFN-b and IFIT1 protein expression infected or stimulated cells were lysed in Laemmli sample buffer. Proteins were detected as described in ''Immunoblotting'' and quantifications were performed as described in ''Quantitative immunoblot analysis.'' Readout by ELISA IFNl1-3 was measured in the supernatant of FLUAV infected cells 32 hr post infection using a IFNl1-3 ELISA kit (PBL-Interferon source, USA) according to the manufacturer's instructions.
Secreted IFN-b from siDAPK1_2 silenced and 5 0 ppp-dsRNA transfected A549 cells were measured using a IFN-b ELISA kit (LumiKine Xpress hIFN-b, InvivoGen, USA) according to the manufacturer's instruction. For accumulative measurements, supernatants were kept on the cells from the start of stimulation until the indicated time point. For measuring secretion rates, medium was changed 1 hr prior to the indicated time point.
